Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover

Osteoporosis International

Volumn 21, Issue 2, 2010, Pages 233-241

  Collette, J ^a,h   Bruyere O ^a   Kaufman, J M ^b   Lorenc, R ^c   Felsenberg, D ^d   Spector, T D ^e   Diaz Curiel, M ^f   Boonen, S ^g   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d HUMBOLDT UNIVERSITY   (Germany)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f Jimenez Diaz Foundation   (Spain)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anti fracture efficacy; Biochemical marker; Bone turnover; Osteoporosis; Strontium ranelate; Vertebral fracture

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIFEDIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR NECK; HIP FRACTURE; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SPINE FRACTURE; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES; THIOPHENES; TREATMENT OUTCOME;

EID: 76549099332     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0940-z     Document Type: Article

References (43)

1. ML Bouxsein D Karasik 2006 Bone geometry and skeletal fragility Curr Osteoporos Rep 4 49 56 10.1007/s11914-006-0002-9 16822403
2. E Seeman 2003 The structural and biomechanical basis of the gain and loss of bone strength in women and men Endocrinol Metab Clin North Am 32 25 38 10.1016/S0889-8529(02)00078-6 1:CAS:528:DC%2BD3sXjtFOjsb8%3D 12699291 (Pubitemid 36378633)
3. E Seeman 2003 Invited review: pathogenesis of osteoporosis J Appl Physiol 95 2142 2151 14555675
4. JJ Stepan F Alenfeld G Boivin, et al. 2003 Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis Endocr Regul 37 227 240
5. P Garnero O Borel PD Delmas 2001 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis Clin Chem 47 694 702 1:CAS:528:DC%2BD3MXis1Kju70%3D 11274020
6. R Civitelli S Gonnelli F Zachei, et al. 1988 Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment J Clin Invest 82 1268 1274 10.1172/JCI113725 1:STN:280:DyaL1M%2FgvVykuw%3D%3D 3262626
7. S Gonnelli C Cepollaro C Pondrelli, et al. 1997 The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis J Bone Miner Res 12 624 631 10.1359/jbmr.1997.12.4. 624 1:CAS:528:DyaK2sXivFens7c%3D 9101374 (Pubitemid 27155222)
8. S Gonnelli C Cepollaro C Pondrelli, et al. 1999 Boner turnover and the response to alendronate treatment in postmenopausal osteoporosis Calcif Tissue Int 65 359 364 10.1007/s002239900713 1:CAS:528:DyaK1MXnsV2nu7w%3D 10541760 (Pubitemid 29514072)
9. J Iwamoto T Takeda Y Sato, et al. 2004 Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis Yonsei Med J 45 676 682 1:CAS:528:DC%2BD2cXoslensbs%3D 15344210 (Pubitemid 39263992)
10. SW Kim DJ Park KS Park, et al. 2005 Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis Endocr J 52 667 674 10.1507/endocrj.52.667 1:CAS:528:DC%2BD28XitVCqu7g%3D 16410657 (Pubitemid 43104669)
11. MJ Seibel V Naganathan I Barton, et al. 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J Bone Miner Res 19 323 329 10.1359/JBMR.0301231 1:CAS:528:DC%2BD2cXhs1elsrs%3D 14969403 (Pubitemid 38116747)
12. DC Bauer P Garnero MC Hochberg, et al. 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial J Bone Miner Res 21 292 299 10.1359/JBMR.051018 1:CAS:528: DC%2BD28Xhs1Kmu7Y%3D 16418785 (Pubitemid 43265295)
13. P Chen JH Satterwhite AA Licata, et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970 10.1359/JBMR.050105 1:CAS:528:DC%2BD2MXlsFehtr0%3D 15883636 (Pubitemid 40712820)
14. PD Delmas AA Licata JY Reginster, et al. 2006 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Bone 39 237 243 10.1016/j.bone.2006.02.003 1:CAS:528:DC%2BD28Xls1ejt70%3D 16563890 (Pubitemid 43851376)
15. PJ Meunier C Roux E Seeman, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis New Engl J Med 350 459 468 10.1056/NEJMoa022436 1:CAS:528:DC%2BD2cXos1Snsw%3D%3D 14749454 (Pubitemid 38133766)
16. JY Reginster E Seeman MC De Vernejoul, et al. 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822 10.1210/jc.2004-1774 1:CAS:528: DC%2BD2MXkt1Wgt78%3D 15728210 (Pubitemid 40686329)
17. PJ Marie P Ammann G Boivin, et al. 2001 Mechanisms of action and therapeutic potential of strontium in bone Calcif Tissue Int 69 121 129 10.1007/s002230010055 1:CAS:528:DC%2BD3MXnslCqur4%3D 11683526 (Pubitemid 32912229)
18. PJ Marie 2005 Strontium ranelate: a novel mode of action of optimizing bone formation and resorption Osteoporos Int 16 Suppl 1 S7 S10 10.1007/s00198-004-1753-8 1:CAS:528:DC%2BD2MXisVSltrc%3D 15578159 (Pubitemid 40768190)
19. C Roux J-Y Reginster J Fechtenbaum, et al. 2006 Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 536 542 10.1359/jbmr.060101 1:CAS:528:DC%2BD28Xkt1Kqsrc%3D 16598373
20. E Seeman J-P Devogelaer R Lorenc, et al. 2008 Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia J Bone Miner Res 23 433 438 10.1359/jbmr.071105 1:CAS:528:DC%2BD1cXjsl2itbo%3D 17997711 (Pubitemid 351304674)
21. PJ Meunier JY Reginster 2003 Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis Osteoporos Int 14 Suppl 3 S66 S76 1:CAS:528:DC%2BD3sXjslWhs7k%3D 12730769
22. HK Genant CY Wu C van Kuijk, et al. 1993 Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 8 1137 1148 1:STN:280:DyaK2c%2FlsFyhuw%3D%3D 8237484
23. HK Genant M Jergas L Palermo, et al. 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis J Bone Miner Res 11 984 996 1:STN:280:DyaK28zptVShtA%3D%3D 8797120
24. DO Slosman DM Provvedini PJ Meunier, et al. 1999 The use of different dual x-ray absorptiometry brands in a multicenter clinical trial J Clin Densitom 2 37 44 10.1385/JCD:2:1:37
25. P Garnero E Sornay-Rendu MC Chapuy, et al. 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis J Bone Miner Res 11 337 349 1:CAS:528:DyaK28Xit1Cgu74%3D 8852944
26. DL Broyles RG Nielsen EM Bussett, et al. 1998 Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase Clin Chem 44 2139 2147 1:CAS:528:DyaK1cXmtlSmt74%3D 9761247
27. P Garnero WJ Shih E Gineyts, et al. 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal women in response to alendronate treatment J Clin Endocrinol Metab 79 1693 1700 10.1210/jc.79.6.1693 1:CAS:528:DyaK2MXislWiuro%3D 7989477
28. AE de Papp HG Bone MP Caulfield, et al. 2007 A cross-sectional study of bone turnover markers in healthy premenopausal women Bone 40 1222 1230 10.1016/j.bone.2007.01.008 17331821 (Pubitemid 46550988)
29. DC Bauer P Garnero JP Bilezikian, et al. 2006 Short-term changes in bone turnover markers and bone mineral density response to parthyroid hormone in postmenopausal women with osteoporosis J Clin Endocrinol Metab 91 1370 1375 10.1210/jc.2005-1712 1:CAS:528:DC%2BD28XjvFOksb0%3D 16449339
30. C Rosenquist C Fledelius S Christgau, et al. 1998 Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin Chem 44 2281 2289 1:CAS:528:DyaK1cXnt1Olt74%3D 9799755
31. LJ Melton 3rd S Khosla EJ Atkinson, et al. 1997 Relationship of bone turnover to bone density and fractures J Bone Miner Res 12 1083 1091 10.1359/jbmr.1997.12.7.1083 9200008 (Pubitemid 27264222)
32. A Rogers RA Hannon R Eastell 2000 Biochemical markers as predictors of rates of bone loss after menopause J Bone Miner Res 15 1398 1404 10.1359/jbmr.2000.15.7.1398 1:CAS:528:DC%2BD3cXltFSiurY%3D 10893690
33. O Löfman P Magnusson G Toss, et al. 2005 Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study Clin Chim Acta 356 67 75 10.1016/j.cccn.2004.12.014 15936304 (Pubitemid 40779887)
34. P Ravn M Rix H Andreassen, et al. 1997 High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women Calcif Tissue Int 60 255 260 10.1007/s002239900225 1:CAS:528:DyaK2sXhsFKhtL8%3D 9069162 (Pubitemid 27106249)
35. P Garnero E Sornay-Rendu B Claustrat, et al. 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15 1526 1536 10.1359/jbmr.2000.15.8.1526 1:CAS:528:DC%2BD3cXlvVSjtrg%3D 10934651
36. J Buehler P Chappuis JL Saffar, et al. 2001 Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis) Bone 29 176 179 10.1016/S8756-3282(01)00484-7 1:CAS:528:DC%2BD3MXlvFWkurg%3D 11502480 (Pubitemid 32734498)
37. E Bonnelye A Chabadel F Saltel, et al. 2007 Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro Bone 42 129 138 10.1016/j.bone.2007.08.043 17945546
38. P Ammann V Shen B Robin, et al. 2004 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats J Bone Miner Res 19 12 20 10.1359/JBMR.040906 (Pubitemid 41103416)
39. A Barbara P Delannoy BG Denis, et al. 2004 Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells Metabolism 53 532 537 10.1016/j.metabol.2003.10.022 1:CAS:528:DC%2BD2cXisVSlsrc%3D 15045704 (Pubitemid 38419200)
40. D Farlay G Boivin G Panczer, et al. 2005 Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone J Bone Miner Res 20 1569 1578 10.1359/JBMR.050405 1:CAS:528:DC%2BD2MXhtVOltrvO 16059629 (Pubitemid 41243546)
41. WD Leslie C Metge L Ward 2003 Contribution of clinical risk factors to bone density-based absolute fracture risk assessment in postmenopausal women Osteoporos Int 14 334 338 10.1007/s00198-003-1375-6 1:STN:280: DC%2BD3s3pt1Cquw%3D%3D 12730741 (Pubitemid 40824250)
42. JA Kanis A Oden O Johnell, et al. 2007 The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporos Int 18 1033 1046 10.1007/s00198-007-0343-y 1:STN:280:DC%2BD2sznvV2hug%3D%3D 17323110 (Pubitemid 47020000)
43. JA Kanis O Johnell A Oden, et al. 2008 FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 397 10.1007/s00198-007-0543-5 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D 18292978